SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story

SomaLogic has completed its all?stock merger with Standard BioTools, combining two specialist life?science platforms into a larger proteomics player. What the deal means for the business model and where the new group positions itself in US diagnostics.

SomaLogic Inc has reached a key turning point with the closing of its all?stock merger with Standard BioTools, creating a combined life?science tools company focused on proteomics and multi?omics workflows, according to a joint announcement dated 01/05/2024 on the companies’ investor pages SomaLogic investor relations as of 05/01/2024 and Standard BioTools investor relations as of 05/01/2024.

The transaction, first announced in late 2023, gives former SomaLogic shareholders a significant minority stake in the new combined entity, which continues under the Standard BioTools name, and aims to accelerate adoption of high?plex proteomics in research and clinical development, according to the merger press releases cited above.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SomaLogic Inc
• Sector/industry: Life?science tools, proteomics
• Headquarters/country: Boulder, United States
• Core markets: Academic research, biopharma, diagnostics development
• Key revenue drivers: Proteomics assays, instruments, data services
• Home exchange/listing venue: Nasdaq (through Standard BioTools)
• Trading currency: US dollar

SomaLogic Inc: core business model

SomaLogic Inc is a US?based life?science tools company that developed a proprietary proteomics platform built around short DNA?based binding molecules known as aptamers. In its public filings, the company has described how these modified aptamers, branded as SOMAmer reagents, are engineered to recognize specific protein targets with high affinity, enabling simultaneous measurement of thousands of proteins in a single biological sample, according to its latest annual report filed on 03/28/2024 with the US Securities and Exchange Commission SEC filing as of 03/28/2024.

The business model historically combined instrument placements, consumable assay kits, and fee?for?service proteomics analysis performed in centralized laboratories. Customers included academic centers, pharmaceutical companies, and other research organizations seeking deep protein?level data to power biomarker discovery, drug development, and risk?prediction models in fields such as cardiovascular disease and oncology, as explained in the same 2023 Form 10?K filing SEC filing as of 03/28/2024.

In addition to hardware and assay sales, SomaLogic sought to monetize its growing proteomic data assets through collaborations and licensed algorithms. The company highlighted how longitudinal protein?expression data could be used to build predictive models for various health states, with the goal of enabling earlier detection and more precise stratification of patients. The data?driven component of the model was designed to complement the recurring consumables revenue typical for life?science tools companies.

Before the merger, SomaLogic generated revenue primarily from assay services delivered from its own laboratories and from partnerships with third?party service providers. The firm also pursued a strategy of placing instruments in key customer labs to expand installed base and assay pull?through. This capital?plus?consumables approach mirrors the broader industry pattern seen across genomics and proteomics tools companies, where recurring consumable sales and service contracts often represent the main profit engine over time.

However, SomaLogic also operated in a competitive and capital?intensive market, with several other proteomics players pursuing high?plex platforms using alternative technologies. Against this backdrop, management positioned the merger with Standard BioTools as a way to build scale, streamline operations, and broaden the combined product portfolio, according to the joint merger announcement on 01/05/2024 SomaLogic investor relations as of 05/01/2024.

Main revenue and product drivers for SomaLogic Inc

Historically, SomaLogic’s revenue has been driven by its SomaScan proteomics assay, a service capable of quantifying thousands of proteins from a single sample. In the 2023 fiscal year, the company reported total revenue of approximately 81 million USD for the period ended 12/31/2023, reflecting growth compared with the prior year as it expanded adoption of its platform, according to its 2023 annual report filed on 03/28/2024 with the SEC SEC filing as of 03/28/2024.

The SomaScan service generated revenue from research customers who sent samples to SomaLogic’s own laboratories or to authorized third?party labs that had adopted the technology. These customers used the multi?protein readouts to identify biomarkers, characterize drug responses, and build signatures that could ultimately be translated into tests. This fee?for?service model was complemented by kit?based offerings that allowed certain partners to run assays on?site, increasing sample throughput and consumables demand over time.

Another revenue contributor for SomaLogic has been strategic collaborations and licensing deals. In past disclosures, the company has described partnerships with pharmaceutical companies and diagnostics developers where it received upfront payments, research funding, or milestone?based compensation tied to the use of its proteomics platform in drug?discovery programs and test development. These agreements added a partnership and licensing revenue stream to the more traditional product and service revenues.

Standard BioTools, formerly known as Fluidigm, brought to the merger a portfolio of microfluidics?based instruments and mass cytometry systems used for genomic and cellular analysis. By combining this installed base with SomaLogic’s high?plex proteomic assays, the new entity aims to offer more integrated workflows to customers, which could increase cross?selling opportunities and reduce customer acquisition costs in the medium term, according to the companies’ joint press materials dated 01/05/2024 Standard BioTools investor relations as of 05/01/2024.

From a financial perspective, management has emphasized expected cost synergies and a path toward improved operating leverage. In an investor presentation released around the time of the merger closing, the combined company outlined plans to rationalize overlapping corporate functions and optimize its R&D footprint, targeting meaningful reductions in annual operating expenses over the next several years, as summarized in materials on the Standard BioTools investor website dated 05/01/2024 Standard BioTools investor presentation as of 05/01/2024.

Revenue growth prospects for the merged entity are closely tied to the broader adoption of proteomics and multi?omics in both academic and industrial research. The companies have noted rising demand for comprehensive protein?level readouts in large?scale cohort studies and clinical?trial biomarker programs. Winning such projects can contribute sizable assay volumes and instrument placements, while also generating data assets that can be leveraged in future collaborations with biopharma partners.

Conclusion

The completed merger between SomaLogic Inc and Standard BioTools marks a significant structural change for both companies and reflects the consolidation trend across the life?science tools sector. SomaLogic’s high?plex proteomics assays, combined with Standard BioTools’ instrumentation and installed base, create a broader platform aimed at serving academic centers and biopharma customers in the United States and internationally. For US?focused investors, key questions now center on how effectively the combined group can execute on promised cost synergies, drive cross?selling, and navigate competition in proteomics and multi?omics. Ongoing integration progress, revenue growth in core assay services, and the ability to manage cash burn will likely remain in focus as the new entity reports its first combined financial results.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.